Neurocrine Biosciences Reports Third Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Neurocrine Biosciences (NBIX) Tops Q3 EPS by 6c
November 5, 2018 4:09 PM ESTNeurocrine Biosciences (NASDAQ: NBIX) reported Q3 EPS of $0.52, $0.06 better than the analyst estimate of $0.46. Revenue for the quarter came in at $151.8 million versus the consensus estimate of $151.83 million.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
... More